Boston Scientific Corporation
BSX
$100.02
$0.970.98%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 60.98% | 145.99% | 36.16% | 12.08% | -6.94% |
| Total Depreciation and Amortization | 11.76% | 8.04% | 6.91% | 11.18% | 2.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 231.15% | -120.67% | 103.70% | 11.22% | -12.86% |
| Change in Net Operating Assets | -73.49% | 211.48% | 8.75% | 668.42% | 194.32% |
| Cash from Operations | 34.03% | 58.18% | 229.88% | 52.14% | 43.55% |
| Capital Expenditure | -1.12% | -1.29% | -4.47% | -3.75% | 5.79% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 77.28% | -2,002.08% | -408.51% | -331.02% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 46.28% | 158.82% | -25.42% | -257.14% | -1,412.50% |
| Cash from Investing | 64.82% | -315.50% | -75.44% | -251.76% | -624.37% |
| Total Debt Issued | -- | -- | -27.37% | -- | 100.00% |
| Total Debt Repaid | -- | -- | -147.83% | -- | 100.00% |
| Issuance of Common Stock | 19.79% | 23.08% | 43.75% | 64.71% | 28.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 95.51% | -2,800.00% | -1.57% | -50.00% | -394.44% |
| Cash from Financing | -1,585.71% | -1,516.67% | -85.15% | 1,326.67% | -56.25% |
| Foreign Exchange rate Adjustments | -133.33% | 300.00% | 657.14% | -325.00% | 220.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -200.00% |
| Net Change in Cash | 277.97% | -131.45% | -78.28% | -2,554.55% | -180.51% |